Therefore, we expected that the effectiveness of COX-2 inhibition for reducing AAAs and aortic rupture when started during the progression-stage of the disease would also correlate with reduced expression of markers of inflammation. The gene discussed is PTGS2; the disease is achalasia-alacrima syndrome.